Haemonetics Announces Sale of Whole Blood Assets to GVS, S.p.A
Portfolio Pulse from
Haemonetics Corporation has announced the sale of its whole blood assets to GVS, S.p.A for up to $67.1 million, including upfront and contingent payments.
December 03, 2024 | 6:30 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Haemonetics Corporation is selling its whole blood assets to GVS, S.p.A for up to $67.1 million. This includes an upfront payment and potential earn-outs, which could impact Haemonetics' financials and strategic focus.
The sale of whole blood assets allows Haemonetics to potentially streamline its operations and focus on other areas of its business. The cash infusion from the sale could strengthen its financial position, making the stock more attractive in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100